Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Cellectar Biosciences, Inc.
University of California, San Francisco
National Cancer Institute (NCI)
Washington University School of Medicine
Deciphera Pharmaceuticals, LLC
Nuvation Bio Inc.
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Emory University
Masonic Cancer Center, University of Minnesota
Laboratorio Elea Phoenix S.A.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Envita Medical Center, Inc.
Thallion Pharmaceuticals